Warung Bebas

Saturday, 30 October 2010

Idiopathic thrombocytopenic purpura

DEFINITION

Patient asks to mbah dukun: "Mbah, my name is Painem, im from Belgia, i have a problem. my son's legs frequently bruising, red spots appear, these has been about 6 months, intermittent, sometimes accompanied by fever, DHF-like disease. Would you tell me what is that?
Mbah Dukun anwers:

ITP, primary immune thrombocytopenia (also called immune (idiopathic) thrombocytopenic purpura), is an autoimmune disease. In autoimmune diseases, the body mounts an immune attack toward one or more seemingly normal organ systems. In ITP, platelets are the target. They are marked as foreign by the immune system and eliminated in the spleen and sometimes, the liver. In addition to increased platelet destruction, some people with ITP also have impaired platelet production.

Thrombocytopenic "means the blood does not have enough red blood cells (platelets). "Purpura" means a person has a lot of bruises (excessive).
ITP occurs when immune system cells (specialized lymphocytes) produce antibodies that cause the destruction of platelets in the spleen and other organs. As such, ITP historically has been considered a disease of platelet destruction. However, recent data also suggest that low platelet counts in the blood may be caused by the inability of the body’s natural processes to produce platelets. Therefore, increasing the rate of platelet production may help address low platelet counts associated with ITP.
There are 2 types of ITP. The first type usually attacks young children, while other types of attacking adults. Children aged 2 to 4 years who generally suffer from this disease. While the ITP for adults, mostly experienced by young women, but can also occur in anyone. ITP is not a hereditary disease.


ETIOLOGY

Patient asks to mbah dukun:What are cause ITP, mbah?
Mbah Dukun anwers:


The specific cause of ITP is unknown. In some cases, ITP has appeared following a viral or bacterial infection, immunizations, exposure to a toxin, or in association with another illness such as lupus or the human immunodeficiency virus (HIV).
Platelets, also called thrombocytes, are specialized blood cells needed to prevent bleeding. Low platelet counts leave adult patients with ITP at risk for bleeding events. The risk of a serious bleeding event increases when platelet counts drop to less than 30,000 platelets per microliter of blood. In extreme cases, death can occur due to an intracerebral hemorrhage (bleeding into the brain).
Normal platelet counts range from 150,000 to 400,000 per microliter of blood. People with platelet counts under 10,000 are more prone to bleed. For many, a count of 30,000 is sufficient to prevent a catastrophic bleed. Individual reactions to low platelet counts differ.


PATHOGENESIS

Autoimmune disease, with anti-platelet antibody formation (usually specific for the platelet GPIIbIIIa receptor) and peripheral platelet destruction. Acute ITP usually occurs in children, follows an acute viral infection or recent live virus immunization, and usually undergoes a spontaneous remission within two months. Chronic ITP is more common in adults, shows an insidious presentation, and lasts > 6 months. The pathogenesis is complex and multifactorial, including a failure of self-antigen recognition and tolerance, altered cytokine secretion, impaired megakarypoiesis, and impaired cellmediated cytotoxicity.


 SYMPTOMS

Patients asks: What are the symptoms of ITP?
Mbah Dukun answers: 

People with ITP often have bruises or small purple spots on their skin (petechiae) where their blood has escaped from their veins or capillaries. Spontaneous bleeding can also occur in the mucus membranes on the inside of the mouth or in the gastrointestinal tract. It is possible, with a decreased number of platelets, to have a spontaneous cerebral hemorrhage.   

In children, signs of serious injury or internal head bleeding include: dizziness, headache that doesn’t go away or gets worse, vomiting, confusion, unusual sleepiness, slurred speech, weakness, numbness or tingling in hands or feet, stiff neck, seizures, eyes not moving together, or inability see. Call your doctor or hospital immediately if your child falls resulting in hitting their head or for any event that causes your child to lose consciousness.
Call your doctor or other healthcare provider immediately if you hit your head or have a serious accident. Watch for a large number of bruises and petechiae, or other signs of severe bleeding, which can indicate a very low platelet count. Signs of bleeding in the brain include: a headache that won’t go away, dizziness, vomiting, unusual sleepiness, confusion, slurring of speech, eyes not moving together, weakness on one side of the body, stiff neck or back, seizures, and inability to see or hear. Notify your doctor about nosebleeds, bleeding gums, or blood in urine, stool or vomit. Even when ITP patients are in remission they should watch for these symptoms so that they can contact their healthcare provider immediately if any of these occur.


DIAGNOSIS

There are no specific tests for ITP; ITP can only be diagnosed by excluding other causes of a low
platelet count. Doctors call this a 'diagnosis of exclusion’. This situation is different from many other diseases. For example, a strep throat is diagnosed with certainty by a positive throat culture for the streptococcus germ, and most cancers are diagnosed with certainty by a positive biopsy. ITP has been defined as isolated thrombocytopenia with no clinically apparent associated conditions or other causes of thrombocytopenia. Isolated thrombocytopenia means that the other components of the blood counts (the red and white blood cells) are normal. The phrase 'clinically apparent’ means that there is no obvious evidence of other disease causing thrombocytopenia even though there might be abnormalities of laboratory tests that suggest another condition. For example, a positive test for antinuclear antibodies (ANA) can be associated with lupus, but when there are no signs or symptoms of another disease (such as lupus) then ITP remains the appropriate diagnosis. On the other hand, if a patient has clinically apparent lupus, with features such as rash, arthritis, kidney disease, and other abnormalities, then ITP is not an appropriate diagnosis because the patient's problems and management will be determined by the course of the lupus, not just by the low platelet count. Although it may seem difficult to make a diagnosis in the absence of a specific, defining 'gold standard’ laboratory test, the diagnostic evaluation for ITP is usually quite simple and straightforward. It most often includes only the basic examination, including a medical history, physical examination, and blood counts with examination of the blood smear. If these are compatible with the diagnosis of ITP and do not suggest other causes for the low platelet count, then the diagnosis is established. Specifically, tests for antibodies against platelets are not required and do not influence treatment decisions (even though antibodies against platelets are the cause of ITP). The indications for doing a bone marrow examination when evaluating a patient for ITP are controversial. In children, it has been recommended that a bone marrow examination is important before treatment with prednisone is begun. This rule was established because prednisone alone may be partially effective in treating for the type of leukemia which is most common in young children, acute lymphocytic leukemia. There is concern that prednisone treatment may thus temporarily mask the presence of leukemia and delay definitive treatment. In practice, however, many pediatric hematologists begin prednisone without doing a bone marrow examination. In older adults, other bone marrow disorders such as myelodysplasia may affect platelet production and a low platelet count may initially be the only abnormality. So in these older patients, a bone marrow examination may be appropriate. A bone marrow examination may also be performed in patients, either children or adults, who do not respond appropriately to treatment. Drug-induced thrombocytopenia, in which an allergic reaction to a drug can cause a low platelet count, is initially indistinguishable from ITP.
Laboratory studies are more valuable in the exclusion of other diseases than in providing definitive evidence of ITP. Variable thrombocytopenia with a normal white blood count and erythrocytic indices (in the absence of severe hemorrhage). Peripheral blood smear examination reveals thrombocytopenia with normal leukocytic and erythrocytic morphology. Coagulation assays are within normal limits. Bone marrow evaluation reveals normal to increased megakaryocytes with normal morphology. Assays for platelet-associated immunoglobulin by ELISA or flow cytometry may be positive, but these assays are presently considered unreliable. Pseudothrombocytopenia must be excluded by peripheral smear examination for platelet clumping. The exclusion of other causes of thrombocytopenia should include other laboratory assays, especially a CBC, Ddimer and FDP assay, LDH, viral serology (especially for HIV), anti-nuclear antibody, rheumatoid factor studies, and ESR, liver function studies, and pregnancy
test.


TREATMENT

Patient asks to mbah dukun: So  What are the main treatments available for ITP?
 Mbah Dukun answers: 

1. Antibiotics
An ITP diagnosis is sometimes associated with an infection and antibiotics can raise the platelet count. There has been considerable research on the success of antibiotics used to treat H-pylori in those diagnosed with ITP. The eradication of other infections can also raise the platelet count.
2. Anti-D
Used to achieve a temporary elevation of the platelet count, the treatment can be repeated for a more extended remedy. The shorter infusion time and often lower cost is an advantage over IVIg. Win Rho SDF and Rhophylac are approved for the treatment of ITP in the US.
3. B-cell depletion
B-cell depletion by a monoclonal antibody (anti-CD20, rituximab) has not been approved by the FDA to treat ITP, although it has become a widely used treatment choice. It works by disabling and changing B-cells, a type of white blood cell. Other anti-CD20 options are in clinical trials.
4. Chemotherapy
Various chemotherapy drugs have been used as a second or third-line treatment choice for chronic ITP patients. Each has a slightly different side effect profile. They have been effective in a small percentage of cases and can be quite toxic. They have not been approved by the FDA to treat ITP.
5. Corticosteroids
Often the first-line treatment for ITP, the dose of corticosteroids (ex. Prednisone) is initially quite high then gradually tapered. Sometimes the platelets remain elevated but in most cases the platelet count recedes as the dose is reduced. An alternate method of administering corticosteroids is an extremely high dose for a few days with no taper. The side effects of corticosteroids can be uncomfortable and grow in severity if the treatment is continued for a long time. While the FDA mentions this as a first-line treatment, it has not been officially approved for the treatment of ITP.
6. Immunoglobulins
An IV drip of immunoglobulin, a type of antibody, is also referred to as IVIg, IGG or IGIV. This treatment is a temporary measure and is not expected to result in a sustained, elevated platelet count, although in some rare cases this does happen. It can be repeated for longer lasting results. IVIg is manufactured by several companies, some of which have received FDA approval for its use in the treatment of ITP.
7. Immunosuppressants
This class of drugs disables parts of the immune system and is often used to prevent the rejection of transplanted organs. These are second and third-line treatments for ITP and have been used to treat other autoimmune diseases such as MS and lupus. None have been approved by the FDA to treat ITP.
8. Modified Testosterone
A synthetic androgen (male sex hormone) is sometimes used to treat ITP when other treatments have failed. It disrupts the action of the pituitary gland, reduces estrogen, halts menses and can cause masculine features for women.
9. Platelet Growth Factors
The newest treatment approach for ITP is the use of platelet growth factors. These agents increase platelets by stimulating the bone marrow to produce more of them. Once thought to be only a disease of platelet destruction, recent research has shown that many people with ITP also have a platelet production problem. Nplate and Promacta have been approved for the treatment of ITP in this category.
10. Splenectomy
This is a surgical procedure where the spleen is removed. The spleen is a large blood filter which, for many people, removes antibody-coated platelets. Theoretically, if the spleen is removed, the platelets will remain in circulation. However, there are other ways the body removes platelets, so this treatment sometimes fails to have a lasting effect.Treatment for ITP is most often coordinated by a hematologist (doctor who specializes in blood disorders). The goals of ITP treatment are to ensure a safe platelet count, prevent bleeding complications, and minimize treatment side effects.

All of these treatments have their own benefits and risks. Side effects have been reported for each of the drugs and treatments for ITP. These side effects will vary from one person to another. You may experience all, some, or none of the side effects. Here are the side effects for frequently used treatments.



 Patient says: thank you mbah for explain, 6 million dollars, I give to mbah Dukun as dowry


references
1. http://www.pdsa.org
2. http://www.pathology.vcu.edu/clinical/coag/ITP.pdf
3. http://www.amgen.com/pdfs/misc/Fact_Sheet_ITP.pdf
4. http://www.ohiohealth.com
5. http://www.hoslink.com






Thursday, 21 October 2010

Chronic Myelogenous Leukemia


 Definition
Chronic Myelocytic leukemia (mieloid, mielogenous, granulocytic, CML) is a disease in which a cell in the bone marrow turn into malignant and produce a large number of granulocytes (a type of white blood cells) are abnormal . When this happens, infectious anemia, or bleeding easily occurs. CML seldom attack individuals under the age of 20 years, but the incidence increases with age.


CML clinical picture similar to the AML, but milder symptoms, namely: In the early stages, CML may not cause symptoms. But some patients may experience fatigue and weakness, loss of appetite, weight loss, fever or sweating at night, full feeling in his stomach (because of an enlarged spleen). Most of the granulocytes leukemic produced in the bone marrow, but some are made in the spleen and liver. In CML, the cells consist of cells that are very young to a mature cell, while the LMA is only found in young cells.
Leukemic Granulocytes tend to shift the normal cells in the bone marrow and often led to the formation of large amounts of fibrous tissue that normal bone marrow depend on During the course of the disease, more and more young granulocytes that enter the bloodstream and bone marrow (acceleration phase). In these phases, anemia and thrombocytopenia (decreased platelet count) and the proportion of young white blood cells (blast cells) increased dramatically. Sometimes granulocytes leukemik experience more change and evolve into blast crisis disease. In blast crisis, the malignant stem cells only produce young granulocytes only, a sign that the disease is getting worse.


Etiology

According to Smeltzer and Bare (2001), although the cause of leukemia is unknown, presdiposistion of genetic and environmental factors seem to play a role. Environmental factors in the form of high-dose radiation exposure pergion accompanied by manifestations of leukemia that arose many years later. Chemicals (eg benzene, arsenic, pesticides, chloramphenicol, fenilbutazone, and antineoplastil agent) is associated with an increased frequency especially alkyl agents.
The cause of most types of leukemia is unknown.
Viruses cause some of leukemia in animals. Virus HTLV-I (human T-cell lymphotropic virus type I), which resemble the virus that causes AIDS, is thought to cause a rare type of leukemia in humans, namely  adult T-cell leukemia .Exposure against radiation (radiation) and certain chemicals ( such as benzene) and the use of anticancer drugs, increases the risk of leukemia. People who have certain genetic abnormalities (eg Down syndrome and Fanconi's syndrome), are also more susceptible to leukemia..



Epidemiology
In Kenya, China, and India, the CML of patients aged 20-40 years. This disease can be about all age groups, both men and women, but rarely found in children aged less than 10 years.



Pathophysiology

In normal circumstances, white blood cells serve as our defense to infection. These cells normally develop in accordance with instructions, can be controlled according to the needs of our bodies. Leukemia increase production of white blood cells in bone marrow that is more than normal. They look different from normal blood cells and does not function as usual. Tues leukemia block production of normal white blood cells, impairing the ability of the body against infection. Tues leukemia also damages other blood cell production in bone marrow, including red blood cells where the cell's function is to supply oxygen to the tissues .

According to Smeltzer and Bare (2001) analysis cytogenic generate a lot of knowledge about the chromosomal aberrations found in patients with leukemia,. Changes may include changes in chromosome numbers, which add or remove an entire chromosome, or changes in the structure, which includes this translocation, two or more chromosomes alter the genetic material, with the development of genes that change is considered cause onset of abnormal cell proliferation.
Chromosomal disorders occur in Ph chromosome (Philadelphia), namely the loss of some long arm of chromosome 22 andtranslocate Darim with the long arm of chromosome 9. So there is a merger between the genes that exist in the long arm of chromosome 9 that ABL with BCR gene located on the long arm of chromosome 22 as look in the picture. Because of this translocation, there was an excessive proliferation of pluripotent stem cells in the system hematopoiesis. In addition to excessive proliferation, white blood cells produced more of survival than normal cells because the gene is anti-apoptotic BCR_ABL. The impact of these two mechanisms, the formation of abnormal clones that finally urged hemopoesis other systems. Eventually these cells control bone marrow and replace the place of cells that produce blood cells are normal. This cancer can also infiltrate into other organs, including liver, spleen, lymph nodes, kidneys and brain.

Signs and symptoms of clinical

CML is divided into 3 phases, namely chronic phase, accelerated phase and blast crisis. Generally, when enforced, the patient still in chronic phase, diagnosis is often discovered accidentally at the time of preoperative preparation, which found great leukocytosis without symptoms of infection.
In the chronic phase, patients often complain of an enlarged spleen or feeling full quickly because of the insistence spleen against the hull. Sometimes there is pain like perur squeezed in the upper right. Other complaints are not specific, among others, feeling tired, weak body, which is not very high fever, night sweats. Weight loss occurred after a prolonged illness. All the complaints above is an illustration of hipermetabolism caused proliferation of leukemia cells.
After 2-3 years, some patients will get worse progressively . Characteristic acceleration phase is a difficult leukocytosis mielosupresif controlled by medication, mieloblast in peripheral 15-30%, promielocyte> 30% and platelets <100.000/mm3. The main complaint of severe anemia, resulting petekie, ekimosis, if accompanied by fever, usually no infection. Fever, enlarged lymph nodes and the formation of lumps of skin that are filled with granulocytes leukemik (kloroma) is a bad omen.


Investigations

According Mbah Dukun stated that investigation of leukemia are:
• A complete blood count showed normocytic, anemia normocytic
• Smear of peripheral blood: normochrom normositer, often found in the polichromate eritroblas asidosis or polikromatofil. Looks all levels of differentiation and maturation of granulocyte series, the percentage of cells increased metamielosit mielocyte and so does the percentage of eosinophils or basophils.
• Hemoglobin: normal or slightly decreased, to less than 10 g/100 ml
• reticulocyte count: the number is usually low
• Platelet count: probably very low (<50.000/mm)
• SDP: more than 50.000/cm with increasing SDP are immature (probably deviated to the left).
• PT / PTT: elongated
• LDH: may increase
• Uric acid serum / urine: may increase
• Copper serum: increased
• Zinc serum: increased
• Bone marrow biopsy: abnormal human resources is usually more than 50% or more of the SDP in the bone marrow. Often 60% - 90% of the blast, with precursor eritroid, mature cells, and megakariositis decline.
• Photos chest and lymph node biopsy: to indicate the degree of involvement.


Chronic Mielogenus  Leukemia Treatment

Most treatments do not cure the disease, but only slow the progression of the disease. Treatment is considered successful if the number of white blood cells can be reduced to less than 50.000/microliter blood. Even the best treatment that can not destroy all cells of leukemic. The only chance of healing is with bone marrow transplantation. Transplantation most effective if done at an early stage and less effective if done on the acceleration phase or blast crisis. . Indication of bone marrow transplantation: 1. Age not more than 60 years, 2. There is a suitable donor, 3. Includes low-risk groups according to the calculation of Sokal.
Drug alpha interferon can normalize bone marrow and cause remission. Hydroxyurea by mouth (swallowed) is the most widely used chemotherapy for this disease. Busulfan is also effective, but because it has serious side effects, then its use should not be too long. Radiation therapy to the spleen sometimes help reduce the number of leukemic cells . Sometimes the spleen must be surgically removed (splenectomy) to: reduce discomfort in the stomach, increasing the number of platelets, reducing the possibility of transfusion.

Hidroxyurea (Hydrea)
• It is elected for induction remission therapy hematologic on LGK.
• More effective than busulfan, melfalan (Alkeran), and Klorambusil.
• Effects mielosupresif still take several days to 1 week after treatment was stopped. Unlike busulfan can cause aplastic anemia and pulmonary fibrosis.
• 30mg/kgBB/day dose given as a single dose or divided into 2-3 doses. If leukocyte> 300.000/mm3, the dose may be raised until maksimal2, 5 grams / day.
• Its use was discontinued when leukocyte <8.000/mm3 or platelets <100.000/mm3
• Drug interactions can occur when used in conjunction with 5-FU, causes neurotoxicity.
• During use hydrea should be monitored Hb, leucocytes, platelets, kidney function, liver function.
Busulfan (myleran)
• Includes an alkyl group which is very strong.
• 4-8mg/dayper oral dose, can be increased up to 12mg/hari.
Should be discontinued if the leukocyte between 10-20.000/mm3, and only started again after leucocytes> 50.000/mm3.
• It should not be given to pregnant women.
• Drug interactions: acetaminophen, cyclophosphamide, and itrakonasol will increase the effect of busulfan, whereas phenytoin would reduce its effect.
• When leucocytes are very high, busulfan administration should be accompanied by either allopurinol and hydration.
• Can cause lung fibrosis and prolonged bone marrow suppression.

Imatinib mesylate (Gleevec = Glyvec)
• Classified as menoklonal antibody designed to inhibit the tyrosine kinase activity of BCR-ABL fusion gene.
• aborted in either the gastric mucosa by oral administration.
• For the clonic phase, 400mg/hari dose after a meal. The dose may be increased to 600mg/hari if not achieve hematologic response after 3 months of delivery, or never achieve a good response but there was deterioration in hemotologik, the hemoglobin is low and / or leucocytes increases with / without a change in platelet counts.
• The dose should be reduced if there neutropeniaweight (<500/mm3) or thrombocytopenia weight (<50.000/mm3) or elevated SGOT / SGPT and bilirubin.
• For accelerate phase or blast crisis phase, can be given directly 800mg/day (400mg bid).
• hypersensitivity reactions can occur, although very rarely.
• It should not be given to pregnant women.
• Drug interactions: ketoconazole, simvastatin and venitoin will enhance the effect of imatinib mesilat.
• In addition to hematologic remission, these drugs can produce remission Cytogenetics characterized by the loss / reduction in Ph chromosome and biological remission was also characterized by reduced expression of BCR-ABL gene or the protein it produces.
• In contrast to imatinib mesilat, interferon can not produce biological remission can achieve remission despite Cytogenetics
• 5 million IU/m2/day subcutaneous dose to achieve remission Cytogenetics, usually after 12 months of therapy. Based on data from studies in Indonesia, which can be tolerated dose is 3 million IU/m2/day. It is now available pegylated interferon preparations, so that the injection once a week, do not need every day.
• Required premedication with analgesic and antipyretic before giving interferon to prevent / reduce the side effects of interferon in the form of flue-like syndrome.
• Drug interactions: theophylline, cimetidine, vinblastine and zidovudin interveron toxin can enhance the effect.
• Exercise caution when given at an advanced age, impaired liver function and kidney weight, patients with epilepsy.
Bone marrow transplant
• It is the definitive therapy for LGK. The data show that bone marrow transplantation (CST) to extend the period of remission up to> 9 years, especially in allogeneic CST.
• Not done on LGK with negative Ph chromosome or BCR-ABL negative.

Thursday, 7 October 2010

CARDIORENAL SYNDROME



DEFINTION
There is no definite definition of the notion Cardiorenal Syndrome (CRS). The National Heart, Lung, and Blood Institute defines the circumstances in which therapy to relieve symptoms of congestive heart failure is limited by the decline in kidney function. More broadly described as a state of moderate or high renal dysfunction, which appears in heart failure patients during therapy. Some say the CRS is the linkage of heart and kidney with the burden of excess fluid in which patients become resistant to diuretic therapy.



Based on the Studies of Left Ventricular Dysfunction (SOLVD), factors associated with decreased kidney function (defined by increased serum creatinine 0.3 mg / dL) were:

• Old age
• low ejection fraction
• Increased level of creatinine
• Low Pressure diastole
• DM
• Hypertension
• The use of antiplatelet, diuretic and β-blockers





PATHOPHYSIOLOGY
Still little knowledge about the pathophysiology of CRS. Decrease in Cardiac Output (CO) in CHF that causes a decrease in renal perfusion, could be an easy explanation. But it has been shown that the decline in kidney function can also occur in ADHF. This contrasts with the statement that the decrease in ejection fraction will lead to renal hypoperfusion and then lead to kidney dysfunction. Thus giving the impression that the pathophysiology of renal dysfunction is more complex than simply decreasing CO.
The model of Guyton explains the relationship component of the heart-kidney, namely Renin-Angiotensin System (RAS), the balance of nitric oxide and reactive oxygen species (NO-ROS), inflammation, and sympathetic nervous system (Sympathetic Nervous System (SNS)) the fourth called Cardiorenal Connection (CRC).




Renin-Angiotensin System (RAS)
When heart failure, a decline in CO and mean arterial blood pressure and renal hypoperfusion and activation of RAS occurs. In kidney failure also occurs inappropriate activation of RAS. In addition to volume retention and vasoconstriction occurs, one of the action on the RAS of the most damaging is the activation of nicotinamide adenine dinucleotide phosphate oxidase (NADPH-oxidase) by Angiotensin II, led to the formation of ROS. NADPH-oxidase have been found elevated in end-stage heart failure.
Angiotensin II causes vascular inflammation via nuclear factor kappa B (NF-кB), which induces production and adhesion molecule kemotatik. RAS also increase sympathetic activity, the situation is found in renal failure.

NO-RO
NO is important in the kidneys for the control of extracellular fluid volume and blood pressure by vasodilation, natriuresis and desensitasi tubuloglomerular feedback. In the CRS NO-ROS imbalance, namely increased production of ROS, decreased antioxidant and decreased NO. Impairment of antioxidants due to oxidative inactivation, decrease in antioxidant vitamins, and disposal of water-soluble antioxidants through dialysis membranes. Oxidative stress is the beginning of the inflammatory response by production (or activation) proinflammatory cytokines, particularly interleukin-1, interleukin-6, C-reactive protein and tumor necrosis factor-alpha (TNFα). These cytokines have an important role in the pathophysiology of atherosclerosis, the negative inotropic effect, cardiac remodeling and thrombotic complications. In vivo and in vitro in mice, oxidative stress increased preganglionic sympathetic nerve activity, increased Artrial Mean Pressure (MAP) and heart rate.
Although not yet completely resolved, oxidative damage in renal tubular or interstitial cells may be involved in the feedback system of the secretion of renin and angiotensin formation in the CRS. Constraints on the synthesis of NO causes chronic cardiac regulation ACE and angiotensin II receptor, which may mediate inflammatory.

Inflammation
It has been estimated to worsen inflammation of heart failure. In patients with heart failure, increased TNF-α and IL-6 found in plasma and myocardium and the nexus with disease progression. Interleukin-18 also terdapt in heart failure after mitral insufficiency. Role of activation of inflammatory cells certainly not very clear, but in CKD and heart failure are chronic inflammatory disorders.
Low-grade inflammation can cause ROS production by activation of leukocytes to remove Oxidative content.

SNS
The first SNS activation of heart failure by baroreflex to provide inotropic and maintain CO. However, excessive sympathetic activity can induce cardiomyocyte apoptosis, hypertrophy and focal myocardial necrosis. Hypertrophy in part due to direct action catecholamines, because some studies indicate noradrenaline induces hypertrophy in cultured cardiomyocyte. In chronic excessive sympathetic activity causes insensitive beta-adrenoreceptor in heart failure and kidney failure. This can cause disruption baroreceptors reflex, reduced heart rate variability decrease and increase state toward arrhythmia.
Sympathetic effects on the kidney to increase renin due to prolonged excessive sympathetic activity has growth-promoting effects on intrarenal vascular wall. This effect is often found mediated by ROS production. SNS can induce inflammation by producing cytokine-mediated noradrenaline from liver and heart, and beta-blockade.
SNS is also releasing neurohormon neuropeptide Y (NPY) involved in vasoconstriction associated with prolonged stress. NPY acts as a trigger of vascular growth, especially in neo-intima formation of blood vessels associated with atherosclerosis. NPY also affect the immune response that is changing the release of cytokines and immune cell function.
So fourth cardiorenal connectors can enlarge the effects of the damage between each other with cardiorenal syndrome as a result.

MANAGEMENT
Until now there is no definitive medical management of heart failure in patients with kidney failure. Treatment is only based on clinical trials. So in this situation is more individualized therapy.

1. ACE inhibitors
ACE inhibitors are known to increase the survival rate in heart failure. However, this drug should be used with caution in renal insufficiency. The Cooperative North Scandinavian Enapril Survival Study (Consensus) shows patients with severe heart failure have increased serum creatinine (> 30%) when using ACE inhibitors. In most patients in which ACE inhibitor was stopped, creatinine levels returned to baseline. Consensus provides good evidence about the benefits of ACE inhibitors in patients with heart failure and renal insufficiency being. But the study did not include patients with severe renal insufficiency (GFR <30 mL / min per 1.73 m2), so that the efficacy and safety of ACE inhibitors in these patients is unknown.
To reduce the incidence of renal failure, ACE inhibitors should be started with low doses, but avoid dehydration and use of common NSAIDs. ACE inhibitors can be delayed if the serum creatinine +6 mg / dL, or GFR <20 mL / min or other contraindications to appear. ACE inhibitors can still be used as long as no worsening renal failure and severe hyperkalemia does not occur

2.  Diuretics
Use of diuretics in the CRS is still very controversial. Several studies have shown aggressive diuresis can worsen kidney function. High-dose diuretics were associated with increased mortality. Because diuretic therapy may worsen renal function and decreased kidney function causing poor results, then the diuretic resistance can be an indicator of poor prognosis of chronic renal failure. However because of lack of definitive data, patients with volume overload state should not barred from granting tiazid loop or diuretics to reduce symptoms.
Some of the factors that create resistance diuretics include: inadequate diuretic dose, excess sodium intake, the late drug absorption, decreased diuretic excretion in the urine and increased sodium reabsorption in the nephron that are not sensitive to the diuretic.
Overcoming resistance diuretic furosemide infusion can be given continuously, starting from 5 mg / h to 10 mg / hour, followed by intravenous thiazide diuretics (usually 250 mg or 500 mg of intravenous chlorothiazide).
When deciding dose diuretics in patients with refractory edema, should be considered in several ways. First, the effective dose should be determined. Also, patients who did not respond with 20 mg of furosemide may not be past the threshold, then the dose should be increased to 40 mg instead of giving the same dose 2 times. Second, patients should limit sodium intake, because high sodium can prevent discharge despite adequate diuretic has been given. Third, patients initially may be given intravenous diuretics for preventing poor oral bioavabilitas due to decreased perfusion and gut motility and mucosal edema also can decrease drug absorption. High dose intravenous diuretics should be given slowly, over 30-60 minutes, to avoid ototoxic.

3. Low-dose dopamine
 Often the effort to increase blood flow to the kidneys and urine output to reduce the incidence of renal failure used low-dose dopamine (approximately 1-3 g / kg / min) or called renal dose. Low-dose dopamine is a non-selective dopaminergic agonists. This can improve renal function by vasodilation (D1 and D2 receptors), saluresis (D1), increased CO (β) and increased renal perfusion (α).
In the experiment by the Australian and New Zealand Intensive Care Society of the effects of low dose dopamine (2 g / kg / min) in the kidneys which was conducted on 2 groups (dopamine group and the placebo group) concluded that no clinically significant protection of kidney failure.

4. Digoxin
Research from The Digitalis Investigation Group (DIG) showed digoxin does not affect life expectancy, but reduced heart failure hospitalizations by 28%. There has been no research on the effects of digoxin in renal failure. To use the safe in patients with heart failure and renal insufficiency, digoxin should be used without a loading dose and with low maintenance dose of 0125 mg.

5. Inotropic
If renal dysfunction in CRS mainly because of low CO, inotropic therapy experiments using dopamine or milrinon can be considered. But its use in CRS is still controversial. Until there is more meaningful data that this drug can be given at a low CO state for a brief period with the monitoring, because of possible risk of arrhythmia.

6. Nesiritide
B-Type natriuretic peptide (BNP) is synthesized in ventricular myocardium due to the response of the widening and overload. BNP mendilatasi arteries and veins, increase the excretion of sodium, and pressing RAS.3 Nesiritide is a synthetic form of BNP has been recognized Food and Drug Administration for the treatment of ADHF. Nesiritide has the effect of venous dilatation, and coronary arteries, reducing preload and afterload, increased CO without direct inotropic effects. causes natriuresis and dieresis, and suppress norepinephrine, endothelin-1, and aldosterone.
At CRS, nesiritide study showed no effect on GFR, renal plasma flow, urine output and sodium excretion. Even in some of the data actually increase the risk of renal insufficiency in patients with heart failure. Further research is needed to determine the role and safety of nesiritide.

7. Ultrafiltration
Ultrafiltration or dialysis is used in patients with chronic volume overload resistant to therapy. Improve kidney dialysis and cardiac hemodynamic responses, but usually used as a palliative in end-stage CRS and can not be given to long term.


PROGNOSIS
By looking at the vagueness of CRS pathophysiology and therapy, these patients have a poor prognosis. Increased serum creatinine or decreased GFR is a poor prognosis. Prognosis worse if accompanied by oliguria, edema, hyponatremia, or resistant to diuretics.


MBAH DUKUN'S ADVICE
Cardiorenal syndrome is a state of interrelations between the heart and kidneys which leads to fluid overload, diuretic resistance and further involve the various systems that bring clinical circumstances will be worse.
Cardiorenal syndrome have a unique and complex pathophysiology. Whatever the degree of renal insufficiency with a combination of heart failure is a challenge in the management of patients and is associated with poor prognosis.
 There are currently no selective therapy for cardiorenal directly affects the connection. Almost all of the current therapies have adverse effects on kidney function. Therefore, good clinical decision is needed in the management of patients.
Large-scale research is needed to determine the definite pathophysiology of cardiorenal syndrome and establish an effective therapy

Wednesday, 22 September 2010

Haemophilia part 2 (Diagnostic and therapy)

ANAMNESTIC

 Until now the family history is still the best way to do the first riddle of the cases of haemophilia, although there are 20-30% of cases of haemophilia, found X chromosome due to spontaneous mutation in the gene encoding F VIII / F IX. A boy - he allegedly suffered from haemophilia, if there is a history of recurrent bleeding (hemartrosis, hematoma) or a history of bleeding after trauma or stretching certain actions with or without family history.

Antenatal diagnosis can actually be done on pregnant women with risk. Examination of factor VIII activity and antigen levels of F VIII in the blood of the fetus in the second trimester fetus can determine the status of the vulnerability of haemophilia A. Identification of F VIII gene and the gene marker for better and more advisable.
A woman suspected of being the bearer of the nature of haemophilia (career) if he has more than one boy or haemophilia patients have one or more brothers and a young boy or his father's haemophilia patients with haemophilia patients. Detection of haemophilia A career can be done by calculating the ratio F VIIIc activity with antigen F VIIIvW. If the value is less than one has accuracy in determining the career of about 90% of haemophilia, but the heart - the heart on the state of pregnancy, hormonal contraceptive use and the presence of liver disease as it can increase the activity factor VIIIc. F VIII activity - average 50% on a career, but sometimes - sometimes <30% and bleeding can occur after trauma or surgery. Genetic analysis using DNA probes, namely by finding polymorphic loci on chromosome X will provide more precise information.
Laboratory
Laboratory abnormalities found in hemostasis testing in disorders, such as lengthening clotting time (CT) and activated partial thromboplastin time (aPTT), thromboplastin generation test abnormality, with the bleeding and the prothrombin (PT) within normal limits.
Definitive diagnosis established by reduced activity of factor VIII / factor IX, and if facilities are available can be performed cytogenetic examination examination seventh marker gene F / F IX. Activity of F VIII / F IX is expressed in U / ml with a mean activity of clotting factor in 1 ml of normal plasma was 100%. Normal value of F VIII activity / F IX was 0.5 to 1.5 U / ml or 50-150%. Must remember is to distinguish haemophilia A with Von Willebrand diseases, by looking at the ratio of F VIIIc: F VIIIag and activity F VW (ristosetin test) lower.

DIFFERENTIAL DIAGNOSTIC

• Haemophilia A and B with a deficiency of factor XI and XII
• Haemophilia A with Von Willebrand disease (especially the Normandy variant), acquired factor VIII inhibitor and a combination of factor VIII deficiency and factor V congenital.
• Haemophilia B with liver disease, the use of warfarin, vitamin K deficiency, F IX inhibitors is very rarely obtained.



SUPPORTIVE THERAPY

Rational treatment of haemophilia is to normalize the levels of factor antihaemophilia. But there are some things that must be considered
• Perform both avoid injury prevention / conflict
• Plan and maintain a surgical level of clotting factor activity approximately 30-50%
• To overcome the acute bleeding that occurs then the first action that rest, ice, compresio, elevation (RICE) at the location of bleeding
1. Corticosteroids. 
Very helpful to eliminate the acute inflammatory process in sinovitis hemartrosis which happened after the attack. Prednisone 0.5 to 1 mg / kg / day for 5-7 days can prevent the occurrence of residual symptoms such as stiff joints (artrosis) that interfere with daily activities and reduced quality of life for haemophilia patients
2. Analgesic.
Analgesic usage is indicated in patients with severe pain hemartrosis, and should be selected analgesic that does not interfere with platelet aggregation (to avoid usage of aspirin and anticoagulants)
3. Medical Rehabilitation. 
Should be performed as early as possible in a comprehensive and holistic in a team, because the delay would cause the management of both physical disability and disability, occupational and psychosocial and medical edukasi.Rehabilitasi arthritis, haemophilia include: training active / passive, cold and heat therapy (liver - liver), ortosis use, psychosocial therapy and therapeutic recreation also education. 
4. Replacement therapy Clotting Factor
Giving clotting factors are given three times a week to avoid a physical disability (especially joints) so that patients can do normal activities. But to achieve that goal is needed of factors antihemofilia (AHF) is quite a lot with the high cost. Clotting factor replacement therapy in cases hemofili done with F VIII or FIX, either recombinant, concentrates, or blood components that contain quite a lot of factors - such clotting factors. The provision made in a few days until the wounds or swelling improved, and particularly during physiotherapy.
Concentrated F VIII / F IX
Haemophilia A severe or mild and moderate to serious bleeding episodes requiring clotting factor correction with high levels should be treated with F VIII concentrate that has been attenuated virus. Factor IX is available in two forms namely prothrombin Complex Concentrates (PCC) which contains F II, VII, IX, X, and purified FIX Concentrates which contain a number of F IX without other factors. PCC can cause paradoxical thrombosis and coagulation due to intravenous spread by a number of other clotting factor concentrates. Risks can be increased in the provision of factor IX concentrate repeated so purified F IX is more desirable.

A. AHF Cryopresiptat
Is one of the non-cellular blood components that are specific plasma concentrates containing F VIII, fibrinogen, factor Vonwillebrand. May be granted if the F VIII concentrates is not found. One bag contains Cryopresiptat 80-100 UF VIII. One bag containing 100 UFCryopresiptat
B. One-deamino 8-D Arginine vasopressin (DDAVP) or desmopresin
Synthetic anti-diuretic hormone (DDAVP) to stimulate increased levels of F VIII activity in plasma up to four times, but it is temporary. Until now the mechanism of DDAVP is not known entirely, but was recommended to be given to mild and moderate haemophilia A and also on women's careers are symptomatic. Giving can be administered intravenously at a dose of 0.3 mg / kg bw in the 30-50 0.9% NaCl for 15-20 minutes with eight-hour work period. Effect on the granting of this peak reached in 30-60 min. In the year 1994 has been issued in the form of concentrates DDAVP intranasal spray. The recommended dose for patients with body weight <50 kg 150 mg (one spray), and 300 mg for patients with BW> 50 kg (twice a spray), with peak effects after 60-90 minutes. Giving DDAVP for the prevention of bleeding events should be performed every 12-24 hrs. Side effects that may occur in the form of tachycardia, flushing, thrombosis and hyponatremia. Angina can also occur in patients with coronary heart disease
C. Antifibrinolitik
Used on the B haemophilia patients to stabilize the clot / fibrin fibrinolysis by inhibiting the process. This proved very helpful in the management of haemophilia patient with bleeding, especially in cases of oral mucosal bleeding caused by the extraction of teeth because saliva contains an enzyme firinolitik. Epsilon Aminocaproic Acid (EACA) can be given orally or intravenously with an initial dose of 200 mg / kg, followed by 100 mg / kg body weight every six hours (maximum of five grams of each delivery). Tranexamic acid is given a dose of 25 mg / kg body weight (maximum 1.5 g) was administered orally or 10 mg / kg BW (maximum 1 g) intravenously every 8 hours. Tranexamic acid can also be reconstituted with 10% of parenteral fluids, especially the normal saline. 
D. Gene Therapy
The study of gene therapy using retrovirus vectors, adenovirus, and adeno - associated virus provides new hope for patients with haemophilia. Currently under intensive research by moving vivo adenovirus vector carrying the gene into liver cells antihaemophilia. F VIII gene are relatively more difficult than the F IX gene, because of its size (9kb) is bigger, but the end of 1998, the experts succeeded in moving the plasmid - based ex vivo factor VIII into the fibroblasts.
E. FFP (the Fresh Frozen Plasma)  clotting blood cell that has been taken from the red blood transfusion of FFP usually  Perform weight depending on whether haemophilia suffered. If patients with severe levels of the patients had to perform a transfusion of FFP 3x a week, but particularly if it was bleeding that resulted kebengkakan specific area then the transfusion should be done every day until the swelling has become lost. One bag containing the plasma, clotting factors, the complement , and plasma protein, the volume of a bag of FFP is 200-250 ml given six hours after the withdrawal, ABO match, 4-6 units could enhance coagulation factor 20-30%.

COMPLICATIONS
Arthropathy hemophilia: the accumulation of intra-articular blood who settled with the result of degeneration of cartilage and bone joints progressively. This causes a decrease until the destruction of joint function. Hemartrosis that are not managed properly can also cause sinovitis chronic synovial tissue inflammation due process is not endless. Joints that often develop complications are knee joints, ankles and elbows.
Prolonged bleeding due to medical action is often found if not done by providing preventive therapy for hemophilia blood clotting factor and weight are in accordance with the kind of medical practice itself (tooth extraction, circumcision, appendectomy, surgery thoracal / intra-abdominal). While bleeding due to trauma are common in everyday situations such as hemartrosis, intramuscular hemorrhage and hematoma. Intracranial hemorrhage is rare, but if  happened, it would be fatal

Friday, 17 September 2010

Hemophilia part 1


Patient asks to Mbah Dukun Bagong: Mbah, i had a friend, he was died 2 months ago, he got bleeding after circumcised, is circumcised dangerous?
Mbah Dukun Bagong answers: "mmmm i see, circumcised is not dangerous, its "sunnah" God commanded Abraham to circumcise his son, Ishmael. However, there is condition, which person can't be able to circumcised, its called HEMOPHILLIA


Hemophilia is a bleeding disease due to deficiency of blood-derived clotting factors (hereditary) by sex - linked recessive on chromosome X (XH). Although hemophilia is a hereditary disease but approximately 20-30% of patients had no family history of blood clotting disorder, so that spontaneous mutation is thought to occur due to endogenous or exogenous environment.

Clotting mechanism is divided into three basic stages:
1) The formation of plasma thromboplastin intrinsic trombopatogenesis also called, began with the work of platelets, especially TF3 and other clotting factors on foreign surfaces or contact with collagen. Clotting factor is factor IV, V, VIII, IX, X, XI, XII and factor III and VII.
2) Changes in prothrombin into thrombin is catalyzed by thromboplastin, F IV, V, VII, and X
3) Changes in fibrinogen into fibrin by thrombin catalyst, TF 1 and TF 2.5


Hemostasis is good progress within a certain time limit so that not only shaped thromboplastin, thrombin or fibrin are important, but also the formation of each Hemophilia is an inherited blood clotting disorder is first recognized and has been well known since 1911. At that time the disease known as hemophilia due to congenital blood clotting disorders in males are derived by a healthy woman. The term hemophilia there is only limited understanding of massive bleeding in boys with a prolonged period of freezing. It turned out that the definition or restriction is not appropriate that it experiences a change, because not all hemophiliacs who accompanied the memanjang.Hal freezing is caused because the examination of blood clotting time is not sensitive.

Until recently recognized 2 types of hemophilia are reduced sex - linked recessive namely: 
  1. Hemophilia A (classical hemophilia), due to deficiency or dysfunction of coagulation factor VIII (F VIII c)

  2. Hemophilia B (Christmas disease) due to deficiency or dysfunction of coagulation factor IX (christmas factor)


Gene factor VIII and factor IX is located on the X chromosome and is recessive, then the disease is carried by women (career, XXh) and manifests clinically in male - male (patient XhY); may manifest clinically in women when both X chromosomes in women there are abnormalities (XhXh).

This disease was first recognized at the Judah family that is around the second century AD in the Talmud. In the early 19th century, modern history new haemophilia, genealogy begins with the British royal family about this disease by Otto (1803). Since it is known as hemophilia blood clotting disorder which reduced X-linked recessive, about half a century before Mendel's laws were introduced. Next, Leggpada 1872 successfully distinguish the disease from the disease hemophilia and other blood-clotting disorders based on clinical symptoms, ie, a disorder which is derived with bleeding tendency muscles and joints that lasts a lifetime. At the beginning of the 20th century, hemophilia was diagnosed based on family history and blood clotting disorders. In the year 1940 - 1950 new experts successfully identify F VIII - FIX deficiency in hemophilia A and B. In 1970 the F VIII were isolated from the carrier protein in plasma, namely von Willebrand factor (vW F), so that now can be distinguished between hemophilia A and von Willebrand disease.
Entering the 21st century diagnostic approaches with advanced technology and providing the necessary coagulation factors capable of carrying patients with hemophilia do other healthy activities such as other people without problems.

DEFINITIONS
Haemophilia derived from Ancient Greek, which consists of two words namely Haima, which means blood and philia, which means love or affection. Hemophilia is a bleeding disease due to deficiency of blood-derived clotting factors (hereditary) by sex - linked recessive on chromosome X (XH). Blood on a hemophiliac can not be frozen by themselves normally. The process of blood clotting in a patient with hemophilia is not as fast and as much as any other normal person. He will require more time for blood clotting process. Patients most susceptible to interference, bleeding under the skin, such as if a little bruising clash, or a bruise incurred by itself if the patient has been doing heavy activity; swelling in the joints, like knee, ankle or elbow. The suffering of the people with hemophilia can cause him any harm if bleeding occurs in the vital organs such as bleeding in the brain.




Patient asks to Mbah Dukun Bagong: Mbah, tell me more about Hemophillia!
Mbah Dukun Bagong answers:

ETIOLOGY
Both types of hemophilia, hemophilia A lack of factor VIII and factor IX deficiency hemophilia B, caused by permanent changes are made to the structure of genes. Genetic mutations play a major role in making proteins needed for blood clotting and that one mutation can cause damage in the process of blood clotting.

CLINICAL MANIFESTATIONS
Bleeding is a typical clinical signs and symptoms are often seen in cases of hemophilia. Bleeding can occur spontaneously or from trauma mild to moderate and can arise when babies begin to learn to crawl. Clinical manifestations depend on the severity of haemophilia (clotting factor activity). Signs of bleeding that is often encountered in the form hemartrosis, hematoma subcutaneous / intramuscular, oral mucosal bleeding, intracranial bleeding, epistaxis, and hematuria. Often, too, found that continuous postoperative bleeding small (circumcision, dental extraction).
Hematrosis most commonly found (85%) with consecutive locations as follows, knee joints, elbows, ankles, shoulder, wrist, and so forth. Hinge joints more often experience joint hemartrosis than ball and sockets, because of his inability to resist rotary motion and angular at the time of voluntary or involuntary movement, while the ball and socket joints better able to withstand the movement because of its function.
Intramuscular hematoma occurred in the muscles - the flexor muscles, particularly in the calf muscle, muscle - the region of the iliopsoas muscle (often in the pelvis) and forearm. Hematoma is often causes significant blood loss, compartment syndrome, nerve compression and muscle contractures. Intracranial bleeding is a major cause of death, can occur spontaneously or after trauma. Retroperitoneal bleeding and airway retrofaringeal dangerous to life threatening. Massive hematuria often found and can cause renal colic but not life threatening. Postoperative bleeding is often continued for several hours to several days, which is associated with poor wound healing.


Tuesday, 14 September 2010

Myasthenia Gravis




DEFINITION


When Mbah Dukun surving on internet, he gets message from Nilla Gustian. Nilla wants information about Myasthenia Gravis.

What is Myasthenia Gravis?
Myasthenia Gravis (MG) is a chronic, autoimmune disease that causes muscle weakness and excessive muscle fatigue. The name comes from Greek and Latin words meaning "grave muscle weakness." But most cases of MG are not as "grave" as the name implies.

The disease can vary in severity and distribution of weakness between individuals, and in any one patient the symptoms fluctuate with relapses and remissions. MG can resolve spontaneously, but for most patients MG persists for life. It can be life threatening, but 90% of patients become symptom-free with modern treatments.
MG produces progressive weakness and fatigue and sporadic abnormal in skeletal muscles, which get worse after exercise and repetition of movement, but can be corrected with drugs antikholineterase.
Usually, this disorder that attacks the muscles controlled by cranial nerves (face, lips, tongue, neck, and throat) but can also attack other muscles.
MG followed the explosion of anger and periodic remissions that can not be predicted. Treatment was not known, but drug therapy can improve symptoms and allow patients to live relatively normal, except during the outburst occurred.
When the disease involves the respiratory system, it can endanger lives.







EPIDEMIOLOGY


Patient asks to Mbah Dukun Bagong: Who is at risk of developing MG and  Is MG hereditary?
Mbah Dukun Bagong answers:

MG affects all races and can develop at any age from childhood to extreme old age. Young patients are more commonly women, whereas older patients, over 50 years, are more often men. People who inherit a tendency to develop autoimmune disease are at increased risk of developing MG, so a patient with MG may have another autoimmune disease, such as diabetes or thyroid disease, or have a relative with autoimmune disease. Occasionally MG develops in patients with rheumatoid arthritis who are given the drug penicillamine. In these cases, the MG symptoms usually disappear when the drug is stopped.
MG is not an inherited disease and does not usually occur in families. This is in contrast to the congenital myasthenic syndromes that are genetic disorders (see below). However, it is thought that an individual’s genetic make-up is one factor, of perhaps many, that leads them to develop MG, and it may occasionally be found in more than one family member. 
Estimates of the number of people affected by MG vary, ranging from 5 to 14 people per 100,000. It occurs in all ethnic groups and both sexes. It most commonly occurs in: 
• young adult women (under 40) 
• older men (over 60)MG can occur at any age. Children sometimes develop it as well. MG is not passed down through the family. You can’t “catch it” from some-one who has it. The disease rarely occurs in more than one member of the same family. If a woman with MG becomes pregnant, sometimes the baby gets antibodies from the mother and has MG symptoms for a few weeks or months after birth. This is called neo-natal myasthenia. The symptoms can be treated and the baby does not have per-manent MG. A group of rare disorders called congeni-tal myasthenic syndromes (CMS) can pro-duce symptoms similar to MG. Unlike MG, these disorders are not autoim-mune disorders but are caused by defec-tive genes. Because of these genes, the nerve-muscle junctions in the body cannot work properly. CMS usually starts at or near birth. But it can start in childhood or even adulthood.


PATHOLOGY

Patient asks to Mbah Dukun Bagong: Tell me pathology of Myasthenia Gravis?
Mbah Dukun Bagong answers:
 
The voluntary muscles of the entire body are controlled by nerve impulses that arise in the brain. These nerve impulses travel down the nerves to the place where the nerves meet the muscle fibers. Nerve fibers do not actually connect with muscle fibers. There is a space between the nerve ending and muscle fiber; this space is called the neuromuscular junction.
When the nerve impulse originating in the brain arrives at the nerve ending, it releases a chemical called acetylcholine. Acetylcholine travels across the space to the muscle fiber side of the neuromuscular junction where it attaches to many receptor sites. The muscle contracts when enough of the receptor sites have been activated by the acetylcholine. In MG, there is as much as an 80% reduction in the number of these receptor sites. The reduction in the number of receptor sites is caused by an antibody that destroys or blocks the receptor site.
Antibodies are proteins that play an important role in the immune system. They are normally directed at foreign proteins called antigens that attack the body. Such foreign proteins include bacteria and viruses. Antibodies help the body to protect itself from these foreign proteins. For reasons not well understood, the immune system of the person with MG makes antibodies against the receptor sites of the neuromuscular junction. Abnormal antibodies can be measured in the blood of many people with MG. The antibodies destroy the receptor sites more rapidly than the body can replace them. Muscle weakness occurs when acetylcholine cannot activate enough receptor sites at the neuromuscular junction. 






SYMPTOMS



Patient asks to Mbah Dukun Bagong: How can we know MG symptoms?
Mbah Dukun Bagong answers:



Dominant symptoms of this disease are skeletal muscle weakness and fatigue. In the early stages, certain muscles are susceptible to fatigue, but no other symptoms. Ultimately, this phenomenon is getting worse and can cause paralysis.Normally, muscles felt strong in the morning and weakened throughout the day, especially after exercise. Short break for a while can restore muscle function. Growing muscle weakness; finally some muscle to not function at all. Symptoms that occur depending on the affected muscle groups; this phenomenon is increasingly becoming the menstrual period and after emotional stress, too long in the sun or the cold or infection.The appearance of symptoms can occur suddenly or from within. In many patients, weak eye closure, the closed eyelids, and double vision is the beginning of this disorder. Patients usually have nasal regurgitation of fluids that often occurs and difficulty chewing and swallowing.Because of this disorder, sufferers are often afraid of choking. Patients also experienced difficulty breathing. Because the eyelids are closed, the patient should raise his head to look toward the back, neck muscles become too weak to support the head without being short.Miastenik crisis patients (respiratory disturbance that appears suddenly) can be susceptible to pneumonia and other respiratory tract infections. This situation can get worse so that it requires mechanical ventilation and airway emergency.





 DIAGNOSE


Patient asks to Mbah Dukun Bagong: How to Diagnose?
Mbah Dukun Bagong answers:



The history and examination of the patient can suggest the diagnosis but it is important to confirm the diagnosis by special investigations: Antibodies to the acetylcholine receptor are found in 85% of patients with generalised MG, and 50% of patients with ocular MG. They are detected by a blood test.
Electromyography (EMG) is performed by a specialist doctor and involves measuring the electrical response in the muscle with a very fine needle. An electrical stimulus is applied to a nerve and the response in the muscle is recorded. It is a very sensitive test, showing an abnormality in most patients with MG, but is not available at all hospitals.
Tensilon® test, an injection of Edrophonium is given which results in a rapid but short-lived improvement in symptoms in many patients.
Chest scan should be done to check whether the thymus is abnormal as many patients with MG have an enlarged thymus, and some have a benign tumour.






Treatments for Myasthenia Gravis (MG)



Patient asks to Mbah Dukun Bagong: How to manage patient with Myasthenia Gravis?
Mbah Dukun Bagong answers:


 There is no known cure for MG, but there are effective treatments that allow many-but not all-people with MG to lead full lives. Common treatments include medications, thymectomy and plasmapheresis. Spontaneous improvement and even remission may occur without specific therapy.
Medications are most frequently used in treatment. Anticholinesterase agents (e.g., Mestinon®) allow acetylcholine to remain at the neuromuscular junction longer than usual so that more receptor sites can be activated. Corticosteroids (e.g., prednisone) and immunosuppressant agents (e.g., Imuran®) may be used to suppress the abnormal action of the immune system that occurs in MG. Intravenous immunoglobulins (IVIg) are sometimes used to affect the function or production of the abnormal antibodies also.
Thymectomy (surgical removal of the thymus gland) is another treatment used in some patients. The thymus gland lies behind the breastbone and is an important part of the immune system. When there is a tumor of the thymus gland (in 10-15% of patients with MG), it is always removed because of the risk of malignancy. Thymectomy frequently lessens the severity of the MG weakness after some months. In some people, the weakness may completely disappear. This is called a remission. The degree to which the thymectomy helps varies with each patient.
Plasmapheresis, or plasma exchange, may be useful in the treatment of MG also. This procedure removes the abnormal antibodies from the plasma of the blood. The improvement in muscle strength may be striking, but is usually short-lived, since production of the abnormal antibodies continues. When plasmapheresis is used, it may require repeated exchanges. Plasma exchange may be especially useful during severe MG weakness or prior to surgery.
Treatment decisions are based on knowledge of the natural history of MG in each patient and the predicted response to a specific form of therapy. Treatment goals are individualized according to the severity of the MG weakness, the patient's age and sex, and the degree of impairment. 






References:


1. http://forum.um.ac.id

2. http://www.myasthenia.org

3. http://www.mdi.ie

4. http://www.neurology.org

5. http://www.wrongdiagnosis.com

6. http://jama.ama-assn.org

Monday, 13 September 2010

NEPHROTIC SYNDROME Part 2


COMPLICATIONS

Patient asks to Mbah Dukun : "Mbah, what are complications of NS?"

Mbah Dukun Bagong answers:



1. Nitrogen balance.

Massive proteinuria in the NS will cause a negative nitrogen balance. Decreased muscle mass is found but these symptoms are often found covered with new symptoms and edema anasarka looked after the edema disappeared. Loss of muscle mass by 10-20% of body mass (lean body mass) are not rare in NS.



2. Hyperlipidemia and Lipiduria.

Hyperlipidemia is a condition that often accompanies SN. Cholesterol levels generally increased, while triglyceride levels vary from normal to slightly rising. Increased cholesterol levels caused by increasing LDL (low density lipoprotein), the major lipoprotein carrier of cholesterol. Trigliserid high levels are associated with increased VLDL (very low density lipoprotein). Also found increased IDL (intermediate density lipoproteins) and lipoprotein (Lp)a, while HDL (high density lipoprotein) cholesterol tends to be normal or low. Mechanism of hyperlipidemia in the NS associated with elevated lipid and lipoprotein synthesis and decreased catabolism of the liver. Originally thought to hyperlipidemia is the result of non-specific stimulation of protein synthesis by the liver. Therefore, no correlation with protein synthesis concluded that hyperlipidemia hyperlipidemia indirectly caused by hipoalbunemia. Hyperlipidemia can be found in the NS with near-normal albumin levels and vice versa in patients with hypoalbuminemia may be a normal cholesterol level. High levels of LDL in the NS due to increased synthesis of heart without interruption catabolism. Improved synthesis and disruption of liver VLDL and IDL conversion into LDL causes high levels of VLDL in the NS. The reduced activity of the enzyme LPL (lipoprotein lipase) are thought to cause reduced VLDL catabolism in the NS. Increased lipoprotein synthesis of the liver caused by pressure or viscosity of plasma. Decrease in HDL cholesterol levels in NS allegedly due to reduced enzyme activity HUW (colesterol acyltransferase lecithin) that function catalyzing the formation of HDL. This enzyme also serves to transport cholesterol and circulation to the liver for catabolism. Decrease in the enzyme activity associated with hypoalbuminemia who allegedly occurred in NS. Lipiduria often found in the SN and is characterized by accumulation of lipids in the cell debris and casts, such as oval fat bodies (oval fat bodies) and fatty casts. Lipiduria more associated with proteinuria than with hyperlipidemia.

3. Hypercoagulability.
Thromboembolic complications are often found in the NS due to increased intravascular coagulation. In the NS occurred due to the tendency GNMN renal vein thrombosis is quite high while the NS on GNMP GN Minimal Lessions and small frequency. Pulmonary embolism and deep venous thrombosis (deep vein thrombosis) are often seen in this NS. Antitrombin caused by loss of (AT) III, protein S, C and plasminogen activating factor in the urine and increased factor V, VII, VIII, X, platelets, fibrinogen, increased platelet aggregation, changes in endothelial cell function and the decrease zimogen factor (factor IX, XI).
4. Calcium and Bone Metabolism
Vitamin D is an important element in calcium and bone metabolism in humans. Vitamin D which banned will be excreted through urine protein causing a decrease in plasma levels. Levels of 25 (OH) D and 12.5 (OH2) D also decreased plasma levels of vitamin D, while free is not susceptible to interference. Therefore, kidney function is generally normal in the NS osteomalasia or uncontrolled hyperparathyroidism is rarely encountered. NS also happen to lose on thyroid hormone binding protein (thyroid binding protein) through urine and decreased levels of plasma thyroxine. And free thyroxine stimulating hormone, thyroxine (thyroxine stimulating hormone) remained clinically normal so do not cause interference.
5. Infection
Before the era of antibiotics, infection is often the cause of death in the NS, especially by organism (encapsulated organism). Infections caused by defects in humoral immunity, cellular, and disruption of the complement system. Decrease in IgG, IgA, and gamma globulin are often found in patients with SN , therefore decreased synthesis or increased catabolism and increased in numbers is wasted through urine. The number of T cells in the circulation is reduced which describes cellular immunity disorders. This is associated with the release of transferrin and zinc are required by T cells to function normally.
6. Impaired Renal Function
NS patients have the potential to occur with acute renal failure through various mechanisms. Decrease in plasma volume or sepsis often causes acute tubular necrosis. Another mechanism which is expected to cause acute renal failure intrarenal edema causing compression of the renal tubules. Nephrotic syndrome can be progressive and developed into PGTA. Proteinuria is a risk factor determinants of the progression of SN. Progression of glomerular damage, glomerulosklerosis developments, and damage associated with proteinuria tubulointerstisium. Hyperlipidemia are also associated with the occurrence mechanism and fibrosis glomerulosklerosis tubulointerstisium on SN, although the role of the progression of the disease is not known with certainty.
7. Other complications
Protein-calorie malnutrition can occur in adults, especially if accompanied NS massive proteinuria, less oral intake, and high catabolism process. Possible toxic effects of drugs that are bound to increase due to hypoalbuminemia causing proteinakan OTC levels in plasma higher. Hypertension is not uncommon as a complication of NS mainly associated with sodium and water retention.


E. NS DIAGNOSE


Patient asks to Mbah Dukun : "Mbah, How to Diagnose NS?"
Mbah Dukun Bagong answers:


NS diagnosis is made based on clinical and laboratory examination of proteinuri massive (> 3.5 g / dl), hipoalbuminemi (<3 g / dl), edema, hiperlipidemi, lipiduri and hypercoagulabilityvenografi required to diagnose venous thrombosis which can occur due to hypercoagulability. In NS primer to determine the type of renal histopathologic abnormalities that determine the prognosis and response to therapy, renal biopsy is necessary.
 In patients can be diagnosed with NS because:

1. From physical examination found the existence of edema anasarka especially in the second leg, both legs and abdomen.
2. From examination laboratorim can be found:
    * Lipd: elevated triglycerides, total cholesterol, and LDL cholesterol
    *  Urine: proteinuria found the existence of twoThe radiological examination did not reveal any abnormality.


TREATMENT

Patient asks to Mbah Dukun : "Mbah, how to treat patient with N?"
Mbah Dukun Bagong answers:


The treatment of NS include specific therapies for disorders or diseases causing kidney foundation (at secondary NS), reduce or eliminate proteinuria, repairing and preventing and overcoming hipoalbuminemi complication. Minimal lesions nephropathy and membranous nephropathy are two disorders that respond well to steroid therapy. Other researchers found that the focal segmental glomerulosklerosis up 40% of patients responded well to steroids with complete remission. Schieppati found that in most patients with idiopathic membranous nephropathy, symptomatic therapy with better kidney function for a long time and can heal spontaneously. Therefore they do not support the use of glucocorticoids and immunosuppressive in this type of nephropathy. Use of corticosteroid regimens in a variety of NS, including prednisone 125 mg once every two days during two months later reduced the dose gradually and stopped after 1-2 months if relapse, therapy may be repeated. Other regimens in adults is prednisone / corticosteroid 1 to 1.5 mg / kg body weight / day for 4 weeks followed by 1 mg / kg of body weight one day intervals for 4 weeks. Up to 90% of patients remission if therapy will be continued until 20-24 weeks, but 50% of patients will experience a relapse after corticosteroid is stopped. Hopper uses doses of 100 mg/48 hours. If there is no progress in 2-4 weeks, the dose was increased to 200 mg per 48 hours and maintained until proteinuri down to 2 grams or less per 24 hours, or until the therapy is considered to no avail. In children given prednisone 60 mg/m2 body surface area or 2 mg / kg body weight / day for 4 weeks, followed by 40 mg/m2 body surface area every two days during four weeks clinical. Respondof corticosteroids can be divided into:

 a. Complete remission
• proteinuri minimal (<200 mg/24 hours)
• Serum albumin> 3 g / dl
• serum cholesterol <300 mg / dl
• Current diuresis and edema disappeared

 b. Partial Remission
 • proteinuri <3.5 g / day
• Serum albumin> 2.5 g / dl
• serum cholesterol <350 mg / dl
• diuresis substandard and still edema

c. Resistant
 • clinical and laboratory showed no change or improvement after four months of treatment with corticosteroids.


Corticosteroids provide a complete remission in 67% cases of minimal lesion nephropathy NS, complete or partial remission in 50% NS membranous nephropathy and 20% -40% in focal segmental glomerulosklerosis. Please note the side effects of long-term corticosteroid use include aseptic necrosis, cataracts, osteoporosis, hypertension, diabetes mellitus. In patients unresponsive to corticosteroids, to reduce proteinuria use symptomatic therapy with angiotensin converting enzyme inhibitor (ACEI), such a low dose of captopril or enalapril, and the dose increased after 2 weeks or non-steroidal antiinflammatory drugs (NSAIDs), such as indomethacin 3 × 50mg. Angiotensin converting enzyme inhibitors reduce glomerular protein ultrafiltration by reducing pressure and improving intrakapiler glomerulus glomerular size selective barrier. Antiproteinuria effects of this drug lasts longer (approximately two months after the drug was stopped). Angiotensin receptor blockers (ARBs) was also able to improve proteinuri because it inhibits inflammation and fibrosis interstisium, inhibiting the release of cytokines, growth factors, adhesion molecules due to the work of local angiotensin II in the kidneys. Combination ACEI and ARB was reported to give greater antiproteinuria effect on primary glomerulonephritis compared with ACEI or ARB use only. Non-steroidal antiinflammatory drugs can be used in patients with membranous nephropathy and focal segmental glomerulosklerosis to reduce prostaglandin synthesis. This causes renal vasoconstriction, decreased glomerular capillary pressure, filtration surface area and reduce proteinuria up to 75%. Besides NSAIDs can reduce the levels of fibrinogen, fibrin-related antigenic and prevent platelet aggregation. However, please note that NSAIDs cause a progressive decline in renal function in some patients. This medicine should not be given if the creatinine clearance <50 ml / min. In patients who frequently relapse with corticosteroids or corticosteroid resistant to other therapies can be used with cyclophosphamide or chlorambucil. Cyclophosphamide gives a longer remission than corticosteroids (75% over two years) with a dose of 2-3 mg / kg bw / day for 8 weeks. Side effects of cyclophosphamide is bone marrow depression, infection, alopecia, hemorrhagic cystitis and infertility if given more than six months. Chlorambucil given at a dose of 0.1 to 0.2 mg / kg bb. / day for 8 weeks. Side effects of chlorambucil is azoospermia and agranulocytosis. Ponticelli and colleagues found that in idiopathic membranous nephropathy, a combination of methylprednisolone and chlorambucil for six months earlier to induce remission and maintain renal function as compared with methylprednisolone alone, but this difference diminished with time (in four years this difference was not significant anymore) . Regimen used was methylprednisolone 1 g / day intravenously for 3 days, then 0.4 mg / kg / day for 27 days followed by peroral chlorambucil 0.2 mg / kg / day one month ago seling. Another alternative therapy membranous nephropathy is cyclophosphamide 2 mg / kg / day plus 30 mg of corticosteroid every 2 days for several months (maximum 6 months). Levamisol a antihelmintic, can be used for minimal lesions nephropathy NS therapy in children with a dose of 2.5 mg / kg body weight every two days at least 112 days. A rare side effect is netropeni, thrombocytopenia and skin rash. Cyclosporine A can be attempted in patients who relapse after being given cyclophosphamide or to prolong remission after administration of corticosteroids. Dose of 3-5 mg / kg / day for six months to one year (after 6 months of reduced doses of 25% every two months). Cyclosporin A can also be used in combination with a corticosteroid in the case of a failed SN in combination with other therapies. Side effects of this drug is hiperplasi gingival, hypertrichosis, hiperurisemi, hypertension and nefrotoksis. Other therapies that have not proven their effectiveness is azatioprin 2 to 2.5 mg / kg / day for 12 months. In the case of NS that were resistant to steroid and drug imunospresan, this time can be given a new immunosuppressive mycophenolate mofetil (MMF), which has the effect of inhibiting the proliferation of B lymphocytes and T lymphocytes, inhibits antibody production of B cells and adhesion molecule expression, inhibit cell proliferation vascular smooth muscle.
Resistance to this diuretic is multifactorial. Hipoalbuminemi Allegedly reduce drug transport to work, while binding by the urine protein is not the main mechanism for this resistance. In such patients can be given intravenous salt-poor human albumin. This therapy is said to increase plasma volume, increased glomerular filtration rate, urine flow and sodium excretion. However, albumin infusion is still doubt its effectiveness as quickly excreted through the urine albumin, other than that can increase blood pressure and even pulmonary edema in patients hipervolemi. Hiperlipidemia in the long term increase the risk of early atherosclerosis. To overcome the barrier can be used hiperlipidemia hidroxymethyl glutaryl co-enzyme A (HMG Co-A) reductase that effectively lower plasma cholesterol. These drugs are said to be most effective with minimal side effects. Gemfibrozil, bezafibrat, klofibrat significantly lower triglyceride levels and slightly lower cholesterol levels. Klofibrat can be toxic at normal levels due to increased levels of free klofibrat cause muscle damage and acute renal failure. Probukol reduce total cholesterol and LDL cholesterol, but minimal effect on triglycerides. Nicotinic acid (niacin) can lower cholesterol and more effective when combined with gemfibrozil. Kolestipol Kolestiramin and effectively lower total cholesterol and LDL cholesterol, but this drug is not recommended because of their effect on intestinal absorption of vitamin D in vitamin D deficiency is exacerbated in the NS. To prevent thromboembolic complications of hypercoagulability that occurs in approximately 20% of cases of NS (most frequently in membranous nephropathy), used dipiridamol (3 x 75 mg) or aspirin (100 mg / day) as an anti-platelet aggregation and deposition of fibrin / thrombus. Besides these drugs can reduce significantly decreased kidney function and the occurrence of end stage renal failure. This therapy is given for patients experiencing nephrotic proteinuri, albumin <2 g / dl, or both. In case of thromboembolism, heparin should be given intravenous / infusion for 5 days, followed by oral warfarin administration until three months or after a healing SN. Giving heparin with activated partial thromboplastin time monitoring (aPTT) 1.5 to 2.5 times control, whereas the effect of warfarin was evaluated by prothrombin time (PT) is usually expressed as International Normalized Ratio (INR) 2-3 times normal. In the event of complications of bacterial infections (pneumococcal pneumonia or peritonitis) are given the appropriate antibiotics and can be accompanied with intravenous immunoglobulin G administration. For pneumococcal vaccine used to prevent infection. The use of immunosuppressive virus infections cause problems such as measles and herpes. Another complication that can occur include hypertension, hypovolaemic shock, acute renal failure, chronic renal failure (after 5-15 years). Handling similar to handling this situation in general. In case of chronic renal failure, in addition to hemodialysis, kidney transplantation can be performed. Dantal et al found in patients with focal segmental glomerulosklerosis who underwent kidney transplants, 15% -55% NS will happen again. Recurrence may be caused by plasma factors (circulating factors) or factors that increase glomerular permeability. Imunoadsorption plasma protein A decrease urine protein excretion in patients with focal segmental NS because glomerulosklerosis, membranous nephropathy and secondary NS because of diabetes mellitus. Imunoadsorpsi suspected release of plasma factors that alter hemodynamic or factors that increase glomerular permeability.
 

Medical and Health Information Copyright © 2012 Fast Loading -- Powered by Blogger